Strategies for multiple signalling inhibition

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 4, 2004, Pages 41-43

  Tortora, G ^a,b   Bianco, R ^a   Daniele, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

EGFR; Therapeutic strategies; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLIC ACID; GEFITINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ANTIBODY; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR ANTIBODY; VATALANIB;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHRONOPHARMACOLOGY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 11244335640     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.supplement-1.41     Document Type: Conference Paper

References (10)

1. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348-1354.
2. Giaccone G, Johnson DH, Manegold C, et al. Gefitinib in combination with gemcitabine and cispatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784.
3. Dancey JE, Freidin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet 2003; 362: 62-64.
4. Cunningham D, Humblet Y, Siena S, et al. A randomized comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
5. Hurwitz H, Fehrenbacher L, Novotny W et a al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
6. Arteaga CL, Baselga J. Clinical trial design and end-points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 2003; 9: 1579-89.
7. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-1857.
8. Bianco R, Shin I, Ritter C, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22: 2812-2822.
9. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-5101.
10. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. Clin Cancer Res 2004; 10: 784-793.